Inactive Instrument

Highlights Genkyotex SA.

Equities

GKTX

FR0013399474

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Calliditas Therapeutics : Acquires Remaining Stake in Genkyotex	21-10-07	MT
Global markets live: Sanofi, ASML, Apple, United Airlines, Netflix...	21-09-29
Genkyotex Sa Reports Earnings Results for the Full Year Ended December 31, 2020	21-02-18	CI
Genkyotex SA Announces Update for Near Term Clinical Development Plan for Setanaxib	21-01-22	CI
Genkyotex Announces Positive Phase 1 Results Demonstrating Favorable Safety and Pharmacokinetic Profile of High-Dose Setanaxib	21-01-18	CI
Calliditas Therapeutics AB (OM:CALTX) completed the acquisition of 37.3% stake in Genkyotex SA.	20-12-10	CI
Genkyotex : Setanaxib Obtains Orphan Drug Designation By European Commission	20-12-08	MT
Genkyotex Sa Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-17	CI
Genkyotex Announces the Enrollment of the 1st Patient in the Phase 2 Trial of Setanaxib in Idiopathic Pulmonary Fibrosis	20-09-14	CI
Calliditas Therapeutics AB (OM:CALTX) made a tender offer to acquire 37.3% stake in Genkyotex SA for €12.1 million.	20-08-12	CI
Genkyotex Announces the Dosing of the First Subjects in Its Phase 1 Study with High-Dose Setanaxib	20-06-30	CI
Genkyotex Provides New Clinical Data from the PBC Phase 2 Trial Providing Further Evidence of the Anti-Fibrotic Activity of Setanaxib	20-06-18	CI
Genkyotex Receives Approval From the French Medicines Agency to Initiate a Phase 1 Clinical Study With High-dose Setanaxib	20-05-13	CI
Genkyotex SA Announces Consolidated Earnings Results for the Year Ended December 31, 2019	20-05-04	CI
Genkyotex’s Setanaxib Significantly Improves Immunotherapy Including Checkpoint Inhibitors in Multiple Preclinical Cancer Models	20-03-03	CI
Genkyotex Sa Reports Earnings Results for the Full Year Ended December 31, 2019	20-02-27	CI
Genkyotex Reports Progress of Setanaxib Phase 2 Investigator Initiated Trials	19-12-03	CI
Genkyotex Announces FDA Approval of Phase 2 Investigator-Initiated Trial with GKT831 in IPF	19-07-17	CI
Genkyotex Announces the Publication of Data in Clinics and Research in Hepatology and Gastroenterology	19-07-01	CI
Genkyotex Announces the Final Results of Its Phase 2 Trial of GKT831 in Primary Biliary Cholangitis	19-06-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Genkyotex SA.

Equities

GKTX

FR0013399474

Highlights

Filters